Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Welcome to the POTP board, the DPP-IV company -- Ignore unavailable to you. Want to Upgrade?

To: rareearth42 who wrote (13)	8/4/2006 4:09:08 PM
From: former_pgs	Read Replies (1) \| Respond to of 90

>Correct me if I'm wrong but in the transcript, management specifically indicated they chose PFS as the primary outcome based on FDA guidance< They stated that they designed the trials around PFS subsequent to the guidance published in 2005 by the FDA. Actually, that guidance is merely an exhaustive look at the various endpoints and the biases or potential problems associated with them. It does note, specifically, that the role of PFS to support licensing varies by cancer setting. I think this was recently shown by the Gemzar approval in ovarian cancer where the PFS data were sufficient. However, I'm at a loss to name a drug that was approved for NSCLC on the basis of PFS. fwiw